🕒 Last update: loading…

Stock RedHill Biopharma Ltd. RDHL

RedHill Biopharma Ltd. — Investlytic score 2/5 on the five criteria.

-
-
40/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 2/5 criteria met.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ✅ Debt passed
  • ✅ P/E passed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: 9.37%

Price change 2019 → 2020: 33.11%

Price change 2020 → 2021: -68.07%

Price change 2021 → 2022: -94.56%

Price change 2022 → 2023: -73.98%

Price change 2023 → 2024: -82.99%

Price change 2024 → 2025: -83.41%

Price change 2025 → 2026: -36.89%

Price change 2026 (year to date): -36.89%

Financial growth

Revenue CAGR (8 years): -38.26%

Earnings CAGR (8 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 0.25

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: 0.10

P/E < 25.0 (maximum threshold).

Correction (6 months)

Current correction: 43.48% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
RedHill Biopharma Ltd.–0.25–🔒
WORK Medical Technology Group Ltd.–0.35−28.4 %–
Spineway S.A.–0.07+9.3 %–
CompuMed, Inc.–0.23+10.2 %–
SpineGuard S.A.–0.27+1.6 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by RedHill Biopharma Ltd. over the latest fiscal years.

Revenue
286,000 USD
fiscal year 2025
Net income
-429,000 USD
fiscal year 2025
Net margin
-150.0 %
fiscal year 2025
Average annual growth
-66.2 %
Revenue growth over 5 years
Average annual growth
+57.7 %
Revenue growth over 10 years
Market cap
1.2 m USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
202064.4 m-76.2 m-118.4 %n/a
202185.8 m-97.7 m-114.0 %+33.2 %
202261.8 m-71.7 m-116.0 %-27.9 %
20236.5 m23.9 m366.2 %-89.4 %
20248.0 m-8.3 m-102.8 %+23.2 %
2025286,000-429,000-150.0 %-96.4 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by RedHill Biopharma Ltd. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
-24.13
risk zone (below 1.81)
Piotroski Score
2 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
0.67 x
low debt
Fiscal year20212022202320242025
Cash and investments38.0 m20.0 m6.4 m4.6 m4.0 m
Total Debt87.8 m123 m1.2 m356,0001.1 m
Net Debt58.3 m103 m-4.4 m-4.3 m-2.9 m
Equity8.9 m-48.4 m2.1 m-4.7 m4.3 m
Total assets181 m159 m23.0 m18.0 m25.3 m
Operating cash flow-65.0 m-29.2 m-35.8 m-9.4 m-9.7 m
Investments (capex)115,000198,00010,9719,0005,000
Free cash-flow-65.2 m-29.4 m-35.8 m-9.4 m-9.7 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-0.32 x
Price / book value-0.54 x
Return on Equity (ROE)-438.2 %
Return on Invested Capital (ROIC)-680.3 %
Net margin-400.5 %
Debt / equity-1.00 x
Current ratio0.34 x
Interest coverage-2.98 x
Free cash-flow yield-697.3 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.

+

Valuation and competitors

RedHill Biopharma Ltd. compared with its sector on the same exchange and with its main competitors.

Sector median P/E
20.8
healthcare, Nasdaq
Sector over 10 years
28.2
10-year median, range 20.4 to 45.8

Direct competitors

CompanyMarket cap (USD)P/ENet margin
RedHill Biopharma Ltd.1.2 mn/a-150.0 %
IM Cannabis Corp. IMCC343,148n/a-20.7 %
Bio Green Med Solution, Inc. BGMS3.5 mn/a-401.3 %
CNS Pharmaceuticals, Inc. CNSP4.2 mn/a0.0 %
Akanda Corp. AKAN3.2 mn/a-17,690.2 %
GlucoTrack, Inc. GCTK179,582n/a0.0 %
Jaguar Health, Inc. JAGX5.6 mn/a-464.2 %
60 Degrees Pharmaceuticals, Inc. SXTP1.8 mn/a-732.8 %
Sector median (Nasdaq)20.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering RedHill Biopharma Ltd. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
10 analysts

Breakdown of ratings

strong buy 0buy 10hold 0sell 0strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 6 times over the last 10 releases.

Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.

+

Dividends and earnings

RedHill Biopharma Ltd.: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Earnings releases

DatePublished EPSExpected EPSSurprise
05/09/2025-1.00-690.00n/a
10/04/2025-1.00-690.00n/a
03/10/2024-1.00-690.00n/a
29/07/2024-2.00-0.30n/a
14/03/2024-0.20-0.03n/a

Stock splits

DateOperation
20/08/2024reverse split: 1 share for 25
23/03/2023reverse split: 1 share for 40

Factual data: ex-dividend history and earnings calendar, as of 20/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in RedHill Biopharma Ltd.

Free float
72.6 %
share of freely traded shares

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 14/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
depositary receipt (ADR)
Listing exchange
Nasdaq
IPO: 07/01/2013
ISIN code
US7574683014
Workforce
35
full-time employees
Chief executive
Dror Ben-Asher

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about RedHill Biopharma Ltd.

What is the RedHill Biopharma Ltd. share price?

Latest recorded price: 0.375 USD on 13/11/2026, for a market cap of 1.2 m USD.

What is the revenue of RedHill Biopharma Ltd.?

286,000 USD for fiscal year 2025, with net income of -429,000 USD (net margin -150.0 %).

What do analysts say about RedHill Biopharma Ltd.?

Out of 10 analysts: 10 buy or strong buy, 0 hold, 0 sell or strong sell.

Is RedHill Biopharma Ltd. stock eligible for the French PEA?

No: this listing is a depositary receipt (ADR), excluded from the PEA.

How many employees does RedHill Biopharma Ltd. have?

35 full-time employees according to the latest published profile.

Who runs RedHill Biopharma Ltd.?

Dror Ben-Asher is the company's chief executive.

07

Similar stocks